Incorporates an active component that will significantly shorten the treatment duration of MPE compared to current catheter devices.
A user-friendly design to promote patient independence, comfort and quality of life.
Reduces the costs associated with long-term home drainage and acute readmissions to hospital.
Posted in News by Mary Faherty
12th January, 2022
An exciting new collaboration is underway in the West of Ireland, bringing disruptive technology into the palliative care space. A consortium of four organisations have joined forces to bring to market...
Read more
Posted in News by Symphysis Medical
4th January, 2022
The SymPhysis Medical team has been working with the National Innovation Centre for Ageing (NICA) at their hub of innovation, The Catalyst, in Newcastle-Upon-Tyne in the UK. In December, the...
Read more
Posted in News by Tim Jones
17th December, 2021
SymPhysis Medical were delighted to be one of 28 companies selected to participate in the NHS Market Access Accelerator 2021. TheHill is an innovation catalyst embedded within Oxford University Hospital’s...
Read more
Posted in News by Symphysis Medical
3rd December, 2021
SymPhysis Medical were thrilled to win Silver in the MedTech category at the 2021 National Startup Awards. The competition highlights the best and brightest early-stage companies in Ireland, providing an...
Read more
Affects ~90% of patients with mesothelioma.
Affects ~ 35% of patients with lung cancer.
Affects ~ 16% of patients with breast cancer.
Affects ~ 11% of patients with lymphoma.
